CONTINUEThis site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Find out more.
  1. Front Page
  2. News By Topic
  3. GlaxoSmithKline Confident In UK HQ Despite Brexit

GlaxoSmithKline Confident In UK HQ Despite Brexit

by Robert Lee,, London

28 July 2016

GlaxoSmithKline (GSK) has announced that it will invest GBP275m (USD363m) in its UK manufacturing network, and said that it views the country as an attractive location for investment.

GSK operates nine sites in the UK, employing approximately 6,000 people. The investment will be concentrated at three of these sites, with the aim of boosting production and supporting the delivery of its latest respiratory and large molecule biological medicines.

GSK said: "The company views the UK as an attractive location for investment in advanced manufacturing due to a number of factors including the skilled workforce, technological and scientific capabilities and infrastructure, and a competitive corporate tax system. This includes the Patent Box, which encourages investment in research and development (R&D) and related manufacturing in the UK by delivering a lower rate of corporation tax on profits generated from UK-owned intellectual property."

GSK's Chief Executive Sir Andrew Witty had supported the campaign for the UK to remain in the European Union (EU). He told the BBC, "We believed a vote to leave would create uncertainty and potentially regulatory change in our industry which from our perspective was unnecessary. But the underlying attractiveness in terms of the UK's economic strengths and its fiscal environment haven't changed and that's why we feel very strongly that this investment makes sense."

Welcoming the announcement, Greg Clark, the Business and Energy Secretary, told the BBC: "An investment of this scale is a clear vote of confidence in Britain and underlines our position as a global business leader. GSK's recognition of our skilled workforce, world leading scientific capabilities, and competitive tax environment is further proof that there really is no better place in Europe to grow a business."

TAGS: Energy | tax | investment | business | tax incentives | public health | private healthcare | intellectual property | corporation tax | United Kingdom | manufacturing | tax breaks | European Union (EU) | research and development | Europe

To see today's news, click here.


Tax-News Reviews

Cyprus Review

A review and forecast of Cyprus's international business, legal and investment climate.

Visit Cyprus Review »

Malta Review

A review and forecast of Malta's international business, legal and investment climate.

Visit Malta Review »

Jersey Review

A review and forecast of Jersey's international business, legal and investment climate.

Visit Jersey Review »

Budget Review

A review of the latest budget news and government financial statements from around the world.

Visit Budget Review »

Stay Updated

Please enter your email address to join the mailing list. View previous newsletters.

By subscribing to our newsletter service, you agree to our Terms and Conditions and Privacy Policy.

To manage your mailing list preferences, please click here »